{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:59:12Z","timestamp":1779141552459,"version":"3.51.4"},"reference-count":77,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transthyretin\u2010related amyloidosis (ATTR) is a subgroup of amyloidosis that results from extracellular misassembled and toxic amyloid deposits affecting multiple organ systems, and cardiac tissues in particular. Because ATTR often presents as heart failure with preserved ejection fraction (HFpEF), it has been largely underdiagnosed. Once considered incurable with a grave prognosis, ATTR cardiomyopathy has seen the development of promising alternatives for diagnosis and treatment, with early diagnosis and treatment of ATTR cardiomyopathy highly beneficial due to its high mortality rate. For instance, diagnosing ATTR cardiomyopathy previously required a cardiac biopsy, but new modalities, such as cardiac magnetic resonance imaging and radionuclide bone scans, show promise in accurately diagnosing ATTR cardiomyopathy. Ongoing research and clinical trials have focused on identifying new treatments which primarily target amyloid fiber formation by inhibiting TTR gene expression, stabilizing the TTR tetramer, preventing oligomer aggregation, or affecting degradation of amyloid fibers. In this review, we describe the advances made in the diagnosis and treatment of ATTR in order to increase awareness of the disease and encourage a lower threshold for ATTR workup. Our review also highlights the need for improving the screening, diagnosis, and treatment guidelines for ATTR cardiomyopathy.<\/jats:p>","DOI":"10.1002\/clc.23434","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T12:35:20Z","timestamp":1596026120000},"page":"1223-1231","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Diagnosis and treatment of transthyretin\u2010related amyloidosis cardiomyopathy"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-6757","authenticated-orcid":false,"given":"Catherine","family":"Teng","sequence":"first","affiliation":[{"name":"Department of Medicine Yale New Haven Health\u2010Greenwich Hospital  Greenwich Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine Saint Vincent Hospital  Worcester Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Young","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Medicine Yale New Haven Health\u2010Greenwich Hospital  Greenwich Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Pan","sequence":"additional","affiliation":[{"name":"Molecular Cardiology Research Texas Heart Institute  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A. F.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Molecular Cardiology Research Texas Heart Institute  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-1417","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Molecular Cardiology Research Texas Heart Institute  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-015-0031-3"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.02.002"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvasa.2012.11.018"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2003.09.001"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9462-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.03.134"},{"key":"e_1_2_11_9_1","first-page":"1","article-title":"Cardiac amyloidosis: clinical manifestations and diagnosis","author":"Fontana M","year":"2020","journal-title":"UpToDate"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-019-00629-5"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-020-00169-4"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-61"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120600877136"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.596"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1300761110"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.11.004"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00653-X"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1371"},{"key":"e_1_2_11_23_1","volume-title":"Heart Failure: A Companion to Braunwald's Heart Disease E\u2010Book","author":"DLM GMF","year":"2019"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0952-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2015.11.013"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005588"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7610"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302353"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2015.05.014"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-016-0308-4"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2009.08.008"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2018.06.011"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.4103\/wjnm.WJNM_9_19"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.8737"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.075"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-014-0310-4"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-200010000-00019"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506120308998998"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2019.0796"},{"key":"e_1_2_11_42_1","first-page":"219","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson MD","year":"2017","journal-title":"Amyloid"},{"key":"e_1_2_11_43_1","unstructured":"FalkRH. 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients.https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT03702829. Accessed April 27 2020."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz298"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0811"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2012.00303.x"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1519507"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"e_1_2_11_49_1","first-page":"88","article-title":"The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: the diflunisal trial","author":"Quarta CCFSR","year":"2014","journal-title":"International Symposium on Amyloidosis"},{"key":"e_1_2_11_50_1","unstructured":"Pereon YannMA et al. Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients with Neuropathy of Unknown Aetiology (PRE\u2010TRANS).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03190577?term=diflunisal&draw=2&rank=6 2020. Accessed April 27 2020."},{"key":"e_1_2_11_51_1","article-title":"The effect of diflunisal on familial amyloidosis","author":"Berk JL","year":"2017","journal-title":"ClinicalTrialsgov"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.700"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100721"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2009.10.062"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0463-z"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2112-1"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-018-1887-x"},{"key":"e_1_2_11_58_1","unstructured":"ClinicalTrialsgov.https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Epigallocatechin+gallate&cntry=&state=&city=&dist= 2020. Accessed April 27 2020."},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1269739"},{"key":"e_1_2_11_60_1","unstructured":"Medicine USNLo. A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy\/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin.https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03481972. Accessed April 27 2020."},{"key":"e_1_2_11_61_1","unstructured":"Medicine NNLo. Multiple Treatment Session Study to Assess GSK2398852 Administered Following and along with GSK2315698.https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03044353. Accessed April 27 2020."},{"key":"e_1_2_11_62_1","unstructured":"TripuraneniR.A Study of PRX004 in Subjects with Amyloid Transthyretin (ATTR) Amyloidosis;2019."},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2016.1148025"},{"key":"e_1_2_11_64_1","unstructured":"National Cancer Institute Drug Dictionary Dezamizumab. National Cancer Institute.https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/794047. Accessed April 27 2020."},{"key":"e_1_2_11_65_1","unstructured":"A Multiple Treatment Session Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together with GSK2315698 in Cohorts of Patients with Cardiac Amyloidosis;2019. Accessed April 27 2020."},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ac60db"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707150-00014"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13025"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.08.025"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.697763"},{"key":"e_1_2_11_71_1","first-page":"991","article-title":"Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope","volume":"70","author":"Gonz\u00e1lez\u2010L\u00f3pez E","year":"2016","journal-title":"Spanish Soc Cardiol"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.2.141"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu506"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(84)80436-2"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2013.10.026"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-019-01490-2"},{"key":"e_1_2_11_77_1","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle RA","year":"1995","journal-title":"Semin Hematol"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.04.015"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.23434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clc.23434","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T17:03:40Z","timestamp":1693847020000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.23434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/clc.23434"],"URL":"https:\/\/doi.org\/10.1002\/clc.23434","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"2020-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}